Company Overview - Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes management [3] - The company's CGM systems, Eversense 365 and Eversense E3, feature a small sensor that is implanted under the skin and communicates with a smart transmitter worn externally, sending glucose data to a mobile app every 5 minutes [3] Financial Results Announcement - Senseonics plans to release its fourth quarter and full year 2024 financial results after market close on March 3, 2025 [1] - A conference call to discuss the financial performance will be held at 4:30 p.m. (Eastern Time) on the same day, with a webcast available on the company's website [2]

Core Viewpoint - Senseonics Holdings, Inc. has filed for CE Mark registration for its Eversense® 365 continuous glucose monitoring (CGM) system, aiming to expand its market presence in the European Union after a successful launch in the United States [1][3][4]. Group 1: Product Overview - Eversense 365 is the world's first and only CGM system designed to last for one year, having received FDA approval in September 2024 and launched in the U.S. in October 2024 [2]. - The Eversense 365 system is an integrated CGM (iCGM) that can work with compatible medical devices, including insulin pumps, as part of an automated insulin delivery (AID) system [6]. Group 2: Market Expansion - The CE Mark submission is in compliance with EU Medical Device Regulation (MDR) and, upon approval, will allow commercialization in EU member countries through Ascensia Diabetes Care, Senseonics' commercial partner [3]. - The initial distribution plans for Eversense 365 in Europe include Germany, Italy, Spain, Poland, Switzerland, and Sweden [3]. Group 3: Impact and Feedback - Feedback from the U.S. launch has been positive, with significant encouragement from endocrinologists, general practitioners, and patients, indicating a tangible impact on the lives of many diabetes patients [5]. - The company aims to provide a 'once a year' solution for glucose control to millions of people living with diabetes in the EU [4]. Group 4: Product Features - Eversense 365 offers several advantages over traditional short-term CGMs, including a longer lifespan, reduced waste, trusted alerts with high accuracy, maximum comfort with gentle adhesives, and consistent reliability with only one calibration required per week [8].

Financial Performance - The Company reported a preliminary unaudited revenue of approximately $8.3 million for Q4 2024 and approximately $22.5 million for the full year ended December 31, 2024[11]. - The unaudited balance of cash, cash equivalents, and restricted cash as of December 31, 2024, is expected to be approximately $74.9 million[11]. - Total unaudited operating expenses and associated cash utilization for Q4 2024 and the full year 2024 were consistent with the Company's previously provided guidance[11]. - The financial information presented is preliminary and has not been reviewed or audited by the Company's independent registered public accounting firm[9]. - The Company anticipates that actual audited financial results may differ from the preliminary financial information provided[9]. Patient Growth - The Company's patient base increased by 56% in 2024 compared to 2023, reaching approximately 6,000 global patients[7]. Corporate Actions - The Company announced the cancellation of the Special Meeting of Stockholders originally scheduled for January 10, 2025, regarding a proposed reverse stock split[6]. Forward-Looking Statements - Forward-looking statements regarding future expectations and plans are subject to various important factors that may cause actual results to differ materially[8]. Company Classification - The Company is classified as an emerging growth company under the Securities Act of 1933[3]. Press Release - The press release detailing these updates was issued on January 8, 2025[4].

GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational, financial and other business updates. Recent Highlights & Accomplishments Generated preliminary unaudited fourth quarter revenue of approximately $8.3 million, and preliminary unaudited full year 2024 total revenue of appro ...

Senseonics Holdings (SENS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this medical technology company would post a loss of $0.03 per share when it actually produced a loss of $0.03, delivering no surprise.Over the last four quarters, the compa ...

Senseonics Holdings, Inc. (NYSE:SENS) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Rick Sullivan - Chief Financial Officer Brian Hansen - President of CGM at Ascensia Diabetes Care Conference Call Participants Brian Langan - Morgan Stanley Vernon Bernardino - H.C. Wainwright Operator Good day, everyone, and welcome to the Senseonics Third Quarter 2024 Earnings Call. At this time, all par ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37717 Senseonics Holdings, Inc. (Exact name of registrant as specified in its charter) Dela ...

Exhibit 99.1 Senseonics Holdings, Inc. Reports Third Quarter 2024 Financial Results GERMANTOWN, Md., November 7, 2024 -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights & Accomplishments: · Eversense365 approved in the US as an integrated con ...

GERMANTOWN, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it will host a virtual KOL event on Friday, October 25, 2024 at 11:00am ET. To register, click here. The event will feature David T. Ahn, MD, and endocrinologist and Chief of Diabetes Services at Hoag Medical Group, and Jeff C ...

Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by Ascensia Diabetes Care underway with a new campaign to highlight the unique benefits of having just one CGM for one full year GERMANTOWN, Md. and ST. LOUIS, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) ("Senseonics" or the "Company"), a medical technology company focused on the devel ...